Carbamazepine
NDC Package 72664-218-10

11-digit billing NDC: 72664021810

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Carbamazepine is epilepsyCarbamazepine tablets is indicated for use as an anticonvulsant drug. Marketed by Vgyaan Pharmaceuticals Llc, this product is identified by NDC 72664-218 and is authorized under FDA application ANDA214328.

Identification & Billing

NDC Package Code
72664-218-10
Package Description
1000 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
72664021810
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Carbamazepine
Dosage Form
-
Usage Information
EpilepsyCarbamazepine tablets is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine tablets as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types:Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types.Generalized tonic-clonic seizures (grand mal).Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine tablets   (see PRECAUTIONS, General). Trigeminal NeuralgiaCarbamazepine tablets is indicated in the treatment of the pain associated with true trigeminal neuralgia.Beneficial results have also been reported in glossopharyngeal neuralgia.This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.

Regulatory & Marketing

Labeler Name
Vgyaan Pharmaceuticals Llc
FDA Application #
ANDA214328
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-19-2020
Listing Expiration
12-31-2025
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (72664-218). Click a package code to view its specific billing and regulatory data.

100 TABLET in 1 BOTTLE
30 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72664-218-10 identifies a specific commercial package of 1000 tablet in 1 bottle of Carbamazepine, labeled by Vgyaan Pharmaceuticals Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Vgyaan Pharmaceuticals Llc on November 19, 2020. The current certification is valid through December 31, 2025.

How is this Vgyaan Pharmaceuticals Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72664021810. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72664-218-10
11-Digit CMS (5-4-2)
72664-0218-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.